Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).

被引：0

作者：

Barthelemy, Philippe

Loriot, Yohann

Voog, Eric

Eymard, Jean Christophe

Ravaud, Alain

Flechon, Aude

Jaillon, Christine Abraham

Chasseray, Matthieu

Lorgis, Veronique

Hilgers, Werner

Gobert, AurElien

Le Moulec, Sylvestre

Simon, Camille

Nicolas, Emanuel

Escande, Anne

Pouessel, Damien

Josse, Constant

Solbes, Marie-Noelle

Lambert, Prisca

Thibault, Constance

机构：

[1] Inst Cancerol Strasbourg Europe, Strasbourg, France

[2] Gustave Roussy, Villejuif, France

[3] Clin Victor Hugo Ctr Jean Bernard, Le Mans, France

[4] Inst Cancerol Jean Godinot, Reims, France

[5] Bordeaux Univ, Bordeaux Univ Hosp, Bordeaux, France

[6] Ctr Leon Berard, Lyon, France

[7] Foch Hosp, Suresnes, France

[8] Ctr Finisterien Radiotherapie & Oncol Clin Pasteu, Brest, France

[9] Inst Cancerol Bourgogne, Dijon, France

[10] Avignon Provence Canc Inst, Avignon, France

[11] St Gregoire Hosp, St Gregoire, France

[12] Clin Marzet, Pau, France

[13] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France

[14] Univ Hosp Nimes, Nimes, France

[15] Clin Ste Anne, Strasbourg, France

[16] Inst Claudius Regaud IUCT Oncopole, Toulouse, France

[17] eXYSTAT, Malakoff, France

[18] Merck Sante SAS, Lyon, France

[19] Pfizer Oncol, Paris, France

[20] Univ Paris Cite, Hop Europeen Georges Pompidou, AP HP Ctr, Inst Canc Paris CARPEM, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

471

引用

页数：1

共 50 条

[41] Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC
Bilen, M. A.
Xi, A. D.
Wong, A.
Schroeder, A.
Kim, R.
Liu, F. X.
Peng, J.
Robinson, S.
Bhanegaonkar, A.
ANNALS OF ONCOLOGY, 2021, 32 : S713 - S713
[42] Interim analysis (IA) of SPADE: A prospective, real-world study of avelumab first-line maintenance (1LM) treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Asia-Pacific (APAC) region
Park, S. H.
Jo, J.
Kim, M.
Shin, S. J.
Kim, I-H.
Huang, Y-H.
Tsai, Y-C.
Oliveira, N.
Rajappa, S. J.
Wang, Y.
Hoffman, J.
Su, P. J.
ANNALS OF ONCOLOGY, 2024, 35 : S1508 - S1509
[43] Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden
Bellmunt, Joaquim
Powles, Thomas
Park, Se Hoon
Voog, Eric
Valderrama, Begona Perez
Gurney, Howard
Ullen, Anders
Loriot, Yohann
Sridhar, Srikala S.
Tsuchiya, Norihiko
Sternberg, Cora N.
Aragon-Ching, Jeanny B.
Petrylak, Daniel P.
Duran, Miguel A. Climent
Tyroller, Karin
Hoffman, Jason
Jacob, Natalia
Grivas, Petros
Gupta, Shilpa
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[44] AVELUMAB FIRST-LINE (1L) MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA (UC): LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY RESPONSE TO 1L CHEMOTHERAPY
Valderrama, Begona
Powles, Thomas
Sridhar, Srikala
Caserta, Claudia
Loriot, Yohann
Gupta, Shilpa
Bellmunt, Joaquim
Sternberg, Cora
Wang, Jing
Costa, Nuno
Laliberte, Robert
di Pietro, Alessandra
Park, Se Hoon
Grivas, Petros
JOURNAL OF UROLOGY, 2023, 209 : E244 - E244
[45] Avelumab first-line maintenance (1LM) in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic: Interim real-world results from a national reimbursement registry.
Zemankova, Anezka
Studentova, Hana
Melichar, Bohuslav
Eid, Michal
Poprach, Alexandr
Kopecky, Jindrich
Spacek, Jan
Stuhlova, Sarka
Dvorak, Jan
Vlcek, Pavel
Zychackova, Katerina
Katolicka, Jana
Blazek, Tomas
Vrana, David
Majkova, Petra
Cepa, Adam
Fiala, Ondrej
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 557 - 557
[46] Real-world treatment characteristics for first-line therapy (1L) of advanced hepatocellular carcinoma (HCC) in Canada and Europe.
Gill, Sharlene
Jaffe, Dena H.
DeCongelio, Marc
DuBell, Arnold N.
Shi, Jing
Wisniewski, Tami
Thompson, Gwilym
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[47] Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US
Carson, K.
Mahmoudpour, H.
Ike, C.
Monzon, S.
Fragkogianni, S.
Ferrer, J.
Kearney, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1215 - S1216
[48] REAL-WORLD ELIGIBILITY AND UTILIZATION OF AVELUMAB MAINTENANCE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
Alicia, K. Morgans
Guru, P. Sonpavde
Vanessa, Shih
Phoebe, Wright
Zsolt, Hepp
Candice, L. Willmon
Nancy, Chang
Steven, Sesterhenn
Boppudi, Naga Sai Sriteja
Thomas, Powles
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S26 - S27
[49] Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance
Sridhar, Srikala S.
Powles, Thomas
Duran, Miguel A. Climent
Park, Se Hoon
Massari, Francesco
Thiery-Vuillemin, Antoine
Valderrama, Begona P.
Ullen, Anders
Tsuchiya, Norihiko
Aragon-Ching, Jeanny B.
Gupta, Shilpa
Petrylak, Daniel P.
Bellmunt, Joaquim
Wang, Jing
Laliberte, Robert J.
di Pietro, Alessandra
Costa, Nuno
Grivas, Petros
Sternberg, Cora N.
Loriot, Yohann
EUROPEAN UROLOGY, 2024, 85 (02) : 154 - 163
[50] J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan
Kikuchi, Eiji
Hayakawa, Nozomi
Nakayama, Masashi
Uno, Masahiro
Nakatsu, Hiroomi
Kitagawa, Chiyoe
Miyake, Hideaki
Yamada, Takeshi
Fujita, Kazutoshi
Shimoyama, Hideaki
Nishihara, Kiyoaki
Kobayashi, Mizuki
Nakamura, Motonobu
Fujimoto, Kiyohide
Sano, Takeshi
Nishiyama, Naotaka
Ito, Takayuki
Kajita, Masahiro
Kobayashi, Takashi
Kitamura, Hiroshi
INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (08) : 859 - 867

← 1 2 3 4 5 →